A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931-Reference-Cited by-同舟云学术

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Published:2018-06-18 Issue: Volume:9 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Ozkaynak M. Fevzi,Gilman Andrew L.,London Wendy B.,Naranjo Arlene,Diccianni Mitchell B.,Tenney Sheena C.,Smith Malcolm,Messer Karen S.,Seeger Robert,Reynolds C. Patrick,Smith L. Mary,Shulkin Barry L.,Parisi Marguerite,Maris John M.,Park Julie R.,Sondel Paul M.,Yu Alice L.

Funder

National Institutes of Health

Alex’s Lemonade Stand Foundation for Childhood Cancer

St. Baldrick’s Foundation

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference27 articles.

1. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma;Yu;N Engl J Med,2010

2. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study;Cheung;Int J Oncol,1998

3. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes;Gillies;J Immunol Methods,1989